# RBC Capital Type: Company (RY) Source: GetYourBrief — https://getyourbrief.com/entity/rbc-capital Canonical HTML page: https://getyourbrief.com/entity/rbc-capital ## Timeline - **2026-06-12**: SEC filings and market close — Stock closes at $27.57, up 2.8%; SEC Form 4 filings reveal the three insider transactions. - **2026-06-11**: Insider sales executed — Directors Kaye, Balachandran, and Meek each sell 1,993 shares at $27.06. - **2026-05-05**: Q1 2026 earnings — uniQure reports revenue of $3.56M (miss) and EPS of -$0.85 (beat by $0.03); net margin remains deeply negative. - **2026-03-09**: RBC upgrade — RBC Capital upgrades uniQure from sector perform to outperform, raising price target from $11 to $35. - **2026-03-03**: TD Cowen Conference — AbbVie management is scheduled to speak at the TD Cowen Health Care Conference. - **2026-02-26**: DOJ Legal Support — The Department of Justice backs AbbVie in its challenge against a Colorado drug discount program law. - **2026-02-25**: RBC Coverage Launch — RBC Capital Markets initiates coverage with an Outperform rating, citing durable growth. - **2023-01-31**: Humira Exclusivity Ends — The first biosimilar for Humira enters the U.S. market, marking the start of the 'Humira cliff'. ## Recent coverage (7 stories, network-wide) ### 3 uniQure Directors Each Sell 1,993 Shares; Stock Now $27.57 2026-08-05 19:24:48 · Sector: bio · Sentiment: Neutral · Impact: 5/10 · Sources: 3 Three uniQure directors each offloaded 1,993 shares at $27.06, pocketing a combined $162K. The gene therapy company’s stock trades above key moving averages after an RBC upgrade, but sales hint at insider caution amid heavy cash burn. Full story: https://getbiobrief.com/story/uniqure-insider-sales-3-directors-sell-1993-shares-27-57 ### Abbott Beats Q2 with $12.59B Revenue, Analysts Raise PT to $134; UNH Also Surges 2026-07-25 20:28:16 · Sector: bio · Sentiment: Positive · Impact: 7/10 · Sources: 1 Abbott Laboratories reported Q2 revenue of $12.59 billion (+13% YoY), beating estimates and raising its full-year EPS guidance. Analysts hiked price targets in response, with BTIG going to $134, reflecting confidence in its diversified healthcare portfolio and pipeline. UnitedHealth also delivered a massive EPS beat, but Abbott’s medtech and diagnostics momentum carries particular relevance for the biopharma sector. Full story: https://getbiobrief.com/story/abbott-unh-q2-2026-beat-analyst-target-hikes-bio ### RBC Bullish on Eli Lilly's Retatrutide Despite Mixed Trial Data 2026-03-20 05:29:58 · Sector: finance · Sentiment: Neutral · Impact: 7/10 · Sources: 2 RBC Capital maintains a positive outlook on Eli Lilly, identifying Retatrutide as a primary growth engine for the pharmaceutical giant. Despite recent mixed clinical trial results, analysts believe the drug's triple-agonist mechanism offers a significant competitive edge in the global obesity market. Full story: https://getfinancebrief.com/story/rbc-capital-eli-lilly-retatrutide-growth-analysis ### RBC Capital Backs Eli Lilly’s Retatrutide as Next-Gen Obesity Powerhouse 2026-03-20 05:29:24 · Sector: bio · Sentiment: Neutral · Impact: 7/10 · Sources: 2 RBC Capital has reaffirmed its bullish outlook on Eli Lilly’s Retatrutide, identifying the triple-agonist as a primary long-term growth driver despite mixed clinical trial data. Analysts suggest that the drug's unprecedented weight-loss efficacy will likely overshadow manageable safety concerns, securing Lilly's dominance in the metabolic health sector. Full story: https://getbiobrief.com/story/eli-lilly-retatrutide-rbc-capital-growth-driver ### Eli Lilly’s Retatrutide Positioned as Next-Gen Obesity Powerhouse by RBC Capital 2026-03-20 05:27:44 · Sector: health · Sentiment: Neutral · Impact: 7/10 · Sources: 2 RBC Capital reaffirms Eli Lilly’s Retatrutide as a critical future growth engine, despite recent mixed clinical trial data. The triple-agonist therapy is expected to redefine the weight-loss market by offering superior efficacy compared to existing dual-agonist treatments. Full story: https://gethealthbrief.com/story/eli-lilly-retatrutide-rbc-capital-growth-driver ### RBC Capital Bullish on AbbVie: Initiates Coverage with Outperform Rating 2026-02-27 14:47:04 · Sector: finance · Sentiment: Neutral · Impact: 5/10 · Sources: 2 RBC Capital has initiated coverage of AbbVie with an 'Outperform' rating, signaling confidence in the company's ability to navigate the post-Humira landscape. Analysts believe the market has over-discounted the growth potential of AbbVie's next-generation immunology drugs and its durable aesthetics portfolio. Full story: https://getfinancebrief.com/story/rbc-capital-abbvie-outperform-rating-analysis ### RBC Capital Initiates AbbVie Coverage with Outperform Rating 2026-02-27 14:46:31 · Sector: bio · Sentiment: Neutral · Impact: 5/10 · Sources: 2 RBC Capital has launched coverage of pharmaceutical giant AbbVie with an Outperform rating, signaling confidence in the company's growth trajectory. The initiation suggests that market concerns regarding biosimilar competition for Humira are overstated as newer immunology assets gain significant market share. Full story: https://getbiobrief.com/story/rbc-capital-abbvie-outperform-rating-analysis --- This page is a machine-readable summary. Sentiment measures the directional read of each development for this entity, not the tone of the reporting; impact weights consequence, not syndication reach. See https://getyourbrief.com/guides/methodology for the full editorial methodology.